EP1904110A4 - Ciblage de cellules présentant un microarn d'expression modifiée - Google Patents

Ciblage de cellules présentant un microarn d'expression modifiée

Info

Publication number
EP1904110A4
EP1904110A4 EP06741167A EP06741167A EP1904110A4 EP 1904110 A4 EP1904110 A4 EP 1904110A4 EP 06741167 A EP06741167 A EP 06741167A EP 06741167 A EP06741167 A EP 06741167A EP 1904110 A4 EP1904110 A4 EP 1904110A4
Authority
EP
European Patent Office
Prior art keywords
microrna expression
targeting cells
altered microrna
altered
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06741167A
Other languages
German (de)
English (en)
Other versions
EP1904110A1 (fr
Inventor
Michael Zenon Michael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICA
Original Assignee
SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICAL CENTRE
SOUTHERN ADELAIDE HEALTH SERVI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICAL CENTRE, SOUTHERN ADELAIDE HEALTH SERVI filed Critical SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICAL CENTRE
Priority to EP11161737A priority Critical patent/EP2377559A1/fr
Publication of EP1904110A1 publication Critical patent/EP1904110A1/fr
Publication of EP1904110A4 publication Critical patent/EP1904110A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/102—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP06741167A 2005-06-03 2006-06-02 Ciblage de cellules présentant un microarn d'expression modifiée Withdrawn EP1904110A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11161737A EP2377559A1 (fr) 2005-06-03 2006-06-02 Ciblage de cellules dotées d'une expression de microARN

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68754705P 2005-06-03 2005-06-03
PCT/AU2006/000750 WO2006128245A1 (fr) 2005-06-03 2006-06-02 Ciblage de cellules presentant un microarn d'expression modifiee

Publications (2)

Publication Number Publication Date
EP1904110A1 EP1904110A1 (fr) 2008-04-02
EP1904110A4 true EP1904110A4 (fr) 2009-02-11

Family

ID=37481150

Family Applications (2)

Application Number Title Priority Date Filing Date
EP11161737A Withdrawn EP2377559A1 (fr) 2005-06-03 2006-06-02 Ciblage de cellules dotées d'une expression de microARN
EP06741167A Withdrawn EP1904110A4 (fr) 2005-06-03 2006-06-02 Ciblage de cellules présentant un microarn d'expression modifiée

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP11161737A Withdrawn EP2377559A1 (fr) 2005-06-03 2006-06-02 Ciblage de cellules dotées d'une expression de microARN

Country Status (5)

Country Link
EP (2) EP2377559A1 (fr)
JP (1) JP2008541737A (fr)
AU (1) AU2006254732A1 (fr)
CA (1) CA2610702A1 (fr)
WO (1) WO2006128245A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1771563A2 (fr) 2004-05-28 2007-04-11 Ambion, Inc. PROCEDES ET COMPOSITIONS FAISANT INTERVENIR DES MOLECULES DE Micro-ARN
ES2534304T3 (es) 2004-11-12 2015-04-21 Asuragen, Inc. Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
WO2008015662A1 (fr) † 2006-08-04 2008-02-07 Dublin City University Procédé d'obtention de produits biologiques recombinants
JP2010504350A (ja) * 2006-09-19 2010-02-12 アシュラジェン インコーポレイテッド 治療的介入の標的としての、ｍｉＲ−２００によって調節される遺伝子および経路
CA2663962A1 (fr) * 2006-09-19 2008-03-27 Asuragen, Inc. Genes regules mir-15, mir-26, mir -31,mir -145, mir-147, mir-188, mir-215, mir-216 mir-331, mmu-mir-292-3p et voies de signalisation utiles comme cibles dans une intervention therapeutique
EP2487240B1 (fr) * 2006-09-19 2016-11-16 Interpace Diagnostics, LLC Micro ARN différemment exprimés dans des maladies pancréatiques et leurs utilisations
EP2094848A2 (fr) * 2006-09-19 2009-09-02 Asuragen, INC. GÈNES ET TRAJETS RÉGULÉS PAR miR-143 COMME CIBLES D'INTERVENTION THÉRAPEUTIQUE
EP2111408A4 (fr) * 2007-01-17 2010-02-03 Univ Johns Hopkins Compositions et procédés comprenant des microarn pour traiter une néoplasie
EP2136846A4 (fr) * 2007-03-26 2011-04-13 Crc For Asthma And Airways Ltd Cibles therapeutique et molecules
CA2683314A1 (fr) * 2007-04-11 2008-10-23 Merck & Co., Inc. Molecules d'acide nucleique isolees correspondant au micro arn 145 (mirna-145) et utilisation de ces dernieres dans le traitement du cancer du colon
AU2008240673A1 (en) * 2007-04-19 2008-10-30 Katholieke Universiteit Leuven, K.U. Leuven R & D Oligonucleotide compositions for the treatment of Alzheimer's disease
CN101883576B (zh) 2007-07-31 2015-08-19 得克萨斯系统大学董事会 调控纤维化的微小rna家族及其用途
WO2009036332A1 (fr) 2007-09-14 2009-03-19 Asuragen, Inc. Microarn exprimés de manière différentielle dans le cancer du col de l'utérus et leurs utilisations
JP2009100687A (ja) * 2007-10-24 2009-05-14 Chiba Univ ｍｉｃｒｏＲＮＡ発現プロファイリングに基づく膀胱癌の検出方法
EP2280078B1 (fr) * 2008-03-27 2016-05-18 Kuroda, Masahiko Marqueur pour la détermination du cancer du sein, méthode d'essai, et kit d'essai
EP2112235A1 (fr) * 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions et procédés pour le profilage de l'expression de microARN du carcinome du nasopharynx
EP2990487A1 (fr) 2008-05-08 2016-03-02 Asuragen, INC. Compositions et procédés relatifs à la modulation de miarn de néovascularisation ou angiogenèse
US20110098346A1 (en) * 2008-05-19 2011-04-28 Agency For Science, Technology And Research Nucleic acid molecule and method of targeting gene expression to gliomas
WO2010075101A2 (fr) * 2008-12-15 2010-07-01 Dcb-Usa, Llc Traitement d'une infection par un picornavirus par ciblage du micro-arn mir-141
SG175839A1 (en) * 2009-04-30 2011-12-29 San Raffaele Centro Fond Gene vector
WO2010135714A2 (fr) * 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Méthodes de modulation de l'expression des adipocytes utilisant des compositions de micro-arn
EP2341145A1 (fr) * 2009-12-30 2011-07-06 febit holding GmbH Empreinte ARNm dans le diagnostic de maladies
WO2011111715A1 (fr) * 2010-03-09 2011-09-15 協和発酵キリン株式会社 Acide nucléique apte à réguler le cycle cellulaire
WO2011112732A2 (fr) 2010-03-12 2011-09-15 The Brigham And Women's Hospital, Inc. Procédés de traitement de troubles inflammatoire vasculaires
US9006201B2 (en) 2010-07-08 2015-04-14 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for diabetes
AU2012212105A1 (en) 2011-02-03 2013-09-12 Mirna Therapeutics, Inc. Synthetic mimics of miR-124
WO2013040251A2 (fr) 2011-09-13 2013-03-21 Asurgen, Inc. Méthodes et compositions incluant mir-135b, permettant de faire la distinction entre un cancer du pancréas et une maladie pancréatique bénigne
ITRM20110685A1 (it) 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
JP5704576B2 (ja) * 2012-12-28 2015-04-22 国立大学法人 千葉大学 ｍｉｃｒｏＲＮＡ発現プロファイリングに基づく膀胱癌の検出方法
JP5704575B2 (ja) * 2012-12-28 2015-04-22 国立大学法人 千葉大学 ｍｉｃｒｏＲＮＡ発現プロファイリングに基づく膀胱癌の検出方法
JP5812361B2 (ja) * 2013-07-11 2015-11-11 国立研究開発法人医薬基盤・健康・栄養研究所 遺伝子発現制御機構を含む新規Ａｄベクター
CN104120128B (zh) * 2014-07-02 2016-04-20 重庆贝羿生物科技有限公司 一种用于促进vhl基因表达的分离的核苷酸分子和促进剂及其制备
CN104726500B (zh) * 2015-03-12 2017-09-12 中国人民解放军第二军医大学 MicroRNA26b‑3p抑制剂在制备人脐带来源间充质干细胞中的应用
CA3001003A1 (fr) * 2015-10-05 2017-04-13 Modernatx, Inc. Procedes d'administration therapeutique de medicaments a base d'acide ribonucleique messager
US11293065B2 (en) 2016-03-14 2022-04-05 Aelan Cell Technologies, Inc. Compositions and methods for the quality control of stem cell preparations
KR20190053179A (ko) * 2016-07-26 2019-05-17 센티 바이오사이언시스, 인코포레이티드 유전자 지우개들
JP7130639B2 (ja) 2016-11-01 2022-09-05 ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク ５－ハロウラシル修飾マイクロｒｎａ及びがんの処置におけるその使用
GB201805287D0 (en) * 2018-03-29 2018-05-16 Univ Edinburgh Haematoietic stem cell treatment
MX2020013667A (es) 2018-06-14 2021-03-02 Ovid Therapeutics Inc Uso de mir-92a o mir-145 en el tratamiento del sindrome de angelman.
CN112301033B (zh) * 2020-11-24 2021-11-19 南通大学 miR-30a-5p及其在促进神经再生和修复周围神经损伤方面的应用
CN113750111A (zh) * 2021-09-23 2021-12-07 清华大学深圳国际研究生院 一种miRNA-15A用于治疗高表达KIF3B肿瘤中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078096A2 (fr) * 2004-02-09 2005-08-25 University Of Massachusetts Oligonucleotides fonctionnels doubles utilises pour reprimer l'expression d'un gene mutant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005054494A2 (fr) * 2003-11-26 2005-06-16 University Of Massachusetts Inhibition sequence-specifique de la fonction du petit arn
EP1713938A2 (fr) * 2004-02-09 2006-10-25 Thomas Jefferson University Diagnostic et traitement de cancers a l'aide de microarn present dans ou au voisinage de caracteristiques chromosomiennes liees aux cancers
EP1784501B1 (fr) * 2004-05-14 2015-11-18 Rosetta Genomics Ltd Arnmi viraux ou associés aux virus et leur utilisation
CN101031658A (zh) * 2004-05-26 2007-09-05 罗塞塔金诺米克斯有限公司 病毒和病毒相关mirna及其用途
US10000757B2 (en) * 2005-05-27 2018-06-19 Ospedale San Raffaele S.R.L. Gene vector

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078096A2 (fr) * 2004-02-09 2005-08-25 University Of Massachusetts Oligonucleotides fonctionnels doubles utilises pour reprimer l'expression d'un gene mutant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHN BINO ET AL: "Human MicroRNA targets.", PLOS BIOLOGY NOV 2004, vol. 2, no. 11, November 2004 (2004-11-01), pages e363, XP009109996, ISSN: 1545-7885 *
MANSFIELD JENNIFER H ET AL: "MicroRNA-responsive 'sensor' transgenes uncover Hox-like and other developmentally regulated patterns of vertebrate microRNA expression", NATURE GENETICS, NATURE PUBLISHING GROUP, NEW YORK, US, vol. 36, no. 10, 1 October 2004 (2004-10-01), pages 1079 - 1083, XP002394622, ISSN: 1061-4036 *
See also references of WO2006128245A1 *

Also Published As

Publication number Publication date
JP2008541737A (ja) 2008-11-27
WO2006128245A1 (fr) 2006-12-07
EP2377559A1 (fr) 2011-10-19
EP1904110A1 (fr) 2008-04-02
CA2610702A1 (fr) 2006-12-07
AU2006254732A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
EP1904110A4 (fr) Ciblage de cellules présentant un microarn d'expression modifiée
IL197444A0 (en) Cell culture improvements
GB2424118B (en) Fuel cells
GB0720484D0 (en) Cells
EP2033230A4 (fr) Systeme de cellules solaires
GB2438352B (en) Cell culture chamber
EP1979951A4 (fr) Cellule solaire
GB0605878D0 (en) Fuel cells
GB0614338D0 (en) Fuel cells
GB0608079D0 (en) Fuel cells
GB0614337D0 (en) Fuel Cells
EP2095430A4 (fr) Cellule solaire
EP2200112A4 (fr) Ensemble de piles
EP2028264A4 (fr) Incubateur de cellules
GB0517382D0 (en) Cell culture
EP2118278A4 (fr) Ciblage genique de cellule souche
EP2095405A4 (fr) Cellules solaires
GB2440366B (en) Solar cells
EP2192402A4 (fr) Electrode a enzyme
EP1723139A4 (fr) Conjugues de ciblage de cellules
GB0503918D0 (en) Cell
GB0606671D0 (en) Cell Culture
GB0601101D0 (en) Solar cell
GB0522564D0 (en) Cells
GB0600960D0 (en) Whole cell biosensor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20071221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SOUTHERN ADELAIDE HEALTH SERVICE - FLINDERS MEDICA

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20090114

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/48 20060101ALI20090108BHEP

Ipc: C12N 15/11 20060101ALI20090108BHEP

Ipc: A61K 48/00 20060101AFI20070202BHEP

Ipc: C12Q 1/68 20060101ALI20090108BHEP

Ipc: A61P 35/00 20060101ALI20090108BHEP

17Q First examination report despatched

Effective date: 20090401

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120323